EMPOWERING ORTHOPAEDIC EXECUTIVES THROUGH STRATEGIC INTELLIGENCE
|
|
What is the last exciting news you recall hearing about DePuy Synthes’ knee franchise? Its competitors have dominated both industry news cycles and the market itself. Rajit Kamal, Vice President and Global Knee Franchise Leader at DePuy Synthes, aims to change that through a combination of hardware and technology, including expansion of ATTUNE and VELYS.
In our interview with Mr. Kamal, he noted DePuy Synthes’ focus on the ASC market. “We expect more than 60% to 70% of total knee replacements will eventually happen in an outpatient setting,” he said. “Cost optimization and efficiency are important constraints within which we innovate.”
|
|
These implant portfolio acquisitions diversify Anika’s revenue streams across a continuum of care in orthobiologics and sports medicine, while positioning the company to expand on a base of fast-growing revenue. Further, Parcus and Arthrosurface fast-track Anika’s buildout of its hybrid salesforce with the addition of 40 direct reps and over 200 distributors.
|
|
|
“Muvr is a full-stack recovery company,” said Robert Winder, Co-Founder and Chief Operating Officer of Muvr Labs. “That means that we have physical therapists to treat patients; we also have technology that assists in the treatment of the patients, including wearable sensors and an app.”
|
|
|
|
COMPANY INITIATIVES
OrthoSensor and McLaren Applied formed EnMovi to expand development of MOTIONSENSE™ wearable smart sensor technology and ORTHOLOGIQ® data analytics for use in orthopedic patient care.
The venture pairs OrthoSensor's years of experience in intelligent sensor-assisted technology with McLaren's Formula 1-derived insights into applications for software, sensor technology, predictive analytics and design..
The transaction includes proprietary implants for the minimally invasive repair of fibula and other fractures, and marks the first step of Conventus' intended expansion into lower extremity orthopedics.
|
|
Johnson & Johnson (JNJ), parent company to DePuy Synthes Companies, continues to strengthen its offerings for digital surgery. At the close of 2019, the company entered into an agreement to acquire the remaining ownership stake in Verb Surgical. Verb's robotics and data science capabilities are expected to enhance JNJ's healthcare leadership and global reach while making medical interventions smarter, less invasive and more personalized.
|
|
|
Many of the lessons that Tom Afzal has applied throughout his career were learned while working at American Hospital Supply Corporation—one of the largest medical device companies in the ‘70s-‘80s—his first professional position after college. As part of a management path program, Mr. Afzal was required to work in many functional areas of the company—sales, marketing, finance, production, R&D, quality, etc.
The experience cemented his personal philosophy: work hard, play hard, enjoy what you do.
|
|
|
PRODUCT PERFORMANCE
AlloAid BioNail features a tapered point and contoured wedge facets to ease insertion, anchor the implant into a fusion site and act as a compressive force to aid fixation.
AlloAid BioNails are resorbed gradually by the surrounding bone, reducing the need for implant removal. The natural engineered allograft also makes the BioNail viable for patients with metal allergies.
SeaSpine commenced full commercial launch of Mariner Midline Posterior Fixation, a comprehensive, less invasive system designed to offer reduced blood loss, incision size and hospital length of stay compared to traditional open procedures.
|
|
Augmedics commenced U.S. launch of the xvision augmented reality guidance system for spine surgery, following FDA 510(k) clearance. The system is available for immediate sale.
xvision Spine allows surgeons to visualize 3D spinal anatomy during surgery as if they had “x-ray vision,” and to navigate instruments and implants while looking directly at the patient, rather than a remote screen.
|
|
|
Spine surgery faces utilization management challenges that are influencing patients’ access to care and surgeons’ abilities to navigate the current payor environment. Device companies can better serve surgeons and their patients by remaining abreast of changes to the payor climate.
|
|
|
The deal includes $480 million in cash and other considerations that bring the transaction total to $490 million, with a targeted close date in the first half of 2020. With the new focus on spine, RTI plans to launch 10 new products during each of the next two years.
|
|
|
|
|
|
|
|
